Provided herein are compositions and kits including a pathogen-inactivated cryoprecipitate suitable for infusion into a subject at least 1 day after thawing. The methods are useful in the efficient preparation of cryoprecipitates with desirable characteristics, including pathogen-inactivated cryoprecipitates that are suitable for infusion into a subject at least 1 day after thawing.

Provided herein are compositions and kits including a pathogen-inactivated cryoprecipitate suitable for infusion into a subject at least 1 day after thawing. The methods are useful in the efficient preparation of cryoprecipitates with desirable characteristics, including pathogen-inactivated cryoprecipitates that are suitable for infusion into a subject at least 1 day after thawing.

A fluid processing system including an integrated blood component collection and pathogen inactivation fluid circuit is disclosed.

A nanocomposition for use in treating a pathogen condition using phthalocyanine dye, such as IR700. A nanocomposition having IR700, an 8PEG nanoparticle and a pathogen targeting peptide. Administering a product comprising IR700 to a patient, whereby the IR700 is delivered to pathogen tissue, and found in only pathogen tissue; and administering light to activate the IR700, thereby producing an ROS.

A polychromatic phototherapy device for blood treatment including a casing having a triple quartz tube cuvette assembly removably installed in the casing, with blood to be treated passing through the cuvette. A plurality of light sources are mounted in the casing adjacent the cuvette to project focused light onto the blood flowing through the cuvette. The light sources include a dual wavelength UVA light source, a UVC light source, and dual wavelength red, an amber, a green and a blue LED light sources. Each of the LED light sources includes a lens assembly that projects a concentrated, highly focused linear light beam on one of the quartz tubes of the cuvette through which the blood is flowing. Once blood has been withdrawn from a patient and treated in the polychromatic phototherapy device, the blood is reinfused back into the patient.

A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.

A device and method can be used for clinical virus inactivation treatment to automatically, continuously and cyclically treat plasma of a patient in a closed system. The disclosed plasma treatment device may be used for an anti-viral agent such as, for example, methylene blue photochemical plasma virus inactivation. The plasma treatment device can perform real-time treatment to the plasma in the closed system on the basis of the principle of plasma exchange and can realize real-time back-transfusion during treatment.

An exposure cell and method for treatment of carbon monoxide poisoning in the blood of a living body by removal of a portion of blood from the body, placing the portion in the exposure cell, exposing the portion in the cell to light of wave length and intensity that causes dissociation of carbon monoxide from hemoglobin, and returning the portion to the body. The exposure cell has an exposure zone outside of the body, that holds the portion, and a window that allows light from outside the zone to enter the zone to disassociate carbon monoxide from the portion. Oxygen is injected into the zone and carbon monoxide is removed from the zone.

Systems and methods for performing low volume (e.g., 500 mL or less) extracorporeal photopheresis (ECP) procedures are disclosed. Each of the different systems and methods eliminates the need for multiple kits and solutions and reduce some of the potential risks inherent in the use of such multiple kits and solutions.

Devices, methods, and systems are provided for priming, separating, and collecting blood components. At least one disposable component may be utilized, and a determination may be made as to whether such a disposable component is authentic, is new/unused or used, or both.